Table 1 Clinical information of DLBCL patients (n = 60) enrolled in untargeted metabolomics.

From: α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis

Characteristics

Numbers

Age (years)

 ≤60

29

 >60

31

Gender

 Male

27

 Female

33

Subtype

 GCB

30

 ABC

30

Ann Arbor stage

 I or II

15

 III or IV

45

NCCN-IPI score

 0–3

35

 4–6

25

Serum LDH levels

 Normal (LDH-ratio ≤ 1)

24

 Upper limit of normal (LDH-ratio > 1)

31

ENI

 Involved site (≤1)

7

 Involved site (> 1)

44

Genetic features

 TP53 loss

7

 TP53 mutant

1

 BCL-6 rearrangement

8

 MYC/BCL-2 rearrangement

1

Expression features

 Double expression

16

Treatment response to 6 cycles of treatments

 CR

10

 PR

7

 SD/PD

6

  1. GCB germinal center B-cell, ABC activated B-cell, NCCN-IPI National Comprehensive Cancer Network-International Prognostic Index, LDH lactate dehydrogenase, ENI extranodal involvement, DHL double-hit lymphoma, CR complete remission, PR partial remission, NR non-remission, SD stable disease, PD progressive disease.
Back to article page